[1] Koh JH, Liew ZH, Ng GK, et al. Efficacy and safety of direct oral anticoagulants versus vitamin K antagonist for portal vein thrombosis in cirrhosis: A systematic review and meta-analysis. Dig Liver Dis,2022,54(1):56-62. [2] Harding DJ,Perera MT,Chen F,et al. Portal vein thrombosis in cirrhosis:Controversies and latest developments. World J Gastroenterol,2015,21(22):6769-6784. [3] Senzolo M, Garcia-Tsao G, García-Pagán JC. Current knowledge and management of portal vein thrombosis in cirrhosis. J Hepatol, 2021,75(2):442-453. [4] Leonardi F,Maria ND,Villa E. Anticoagulation in cirrhosis:a newparadigm. Clin Mol Hepatol,2017,23(1):13-21. [5] Stine JG,Shah PM,Cornella SL,et al.Portal vein thrombosis,mortality and hepatic decompensation in patients with cirrhosis: A meta-analysis .World J Hepatol,2015,7( 27) : 2774-2780. [6] Qi XS,Su CP,Ren WR,et al.Association between portal vein thrombosis and risk of bleeding in liver cirrhosis: A systematic review of the literature. Clin Res Hepatol Gastroenterol,2015,39( 6):683-691. [7] 车莹,黄晓铨,陈世耀.用循证观点看待肝硬化门静脉血栓诊治中的争议.肝脏,2022,27(3):261-264. [8] Biolato M, Paratore M, Di Gialleonardo L, et al. Direct oral anticoagulant administration in cirrhotic patients with portal vein thrombosis: What is the evidence? World J Hepatol, 2022,14(4):682-695. [9] 靳珂珂, 丁惠国. 肝硬化门静脉血栓形成风险监测及抗凝管理.实用肝脏病杂志,2024, 27(1): 3-6. [10] Chun HS, Choe AR, Lee M, et al. Treatment of direct oral anticoagulants in patients with liver cirrhosis and portal vein thrombosis. Clin Mol Hepatol,2021,27(4):535-552. [11] Fontana RJ. Prophylactic anticoagulation in cirrhotics: a paradox for prime time? Gastroenterology, 2012,143(5):1138-1141. [12] 刘壮,陈纪宏,祁兴顺,等.门静脉血栓动物模型的建立和应用.临床肝胆病杂志,2024.40(1):29-32. [13] Wang Z, Chen Z, Fan Z, et al. Traditional Chinese medicine on treating splenomegaly due to portal hypertension in cirrhosis: A protocol for systematic review and meta-analysis. Medicine (Baltimore), 2021,100(1):e24081. [14] Zhang DQ, Mu YP, Xu Y, et al. Research progress in Chinese medicine preparations for promoting blood circulation and removing blood stasis for cirrhotic patients with portal vein thrombosis following splenectomy. Chin J Integr Med, 2022,28(9):855-863. [15] Wei C, Qiu J, Wu Y,et al.Promising traditional Chinese medicine for the treatment of cholestatic liver disease process (cholestasis, hepatitis, liver fibrosis, liver cirrhosis). J Ethnopharmacol, 2022,297:115550. [16] Guo Y, Dong S, Li M, et al. A new model of portal vein thrombosis in rats with cirrhosis induced by partial portal vein ligation plus carbon tetrachloride and intervened with rivaroxaban. BMC Gastroenterol, 2024,24(1):161. [17] 张津瑜,陈文显,沈华,等.大鼠门静脉系统血栓形成模型的建立和观察.中国普通外科杂志,2018,27(6):724-731. [18] 吴治念,肖滢,王亚东.肝硬化门静脉血栓形成机制和治疗新认识.中华肝脏病杂志,2022,30:(11):1280-1284. [19] 张明.肝硬化门静脉血栓形成诊治新进展.实用肝脏病杂志, 2024, 27(1): 11-15. [20] 中华医学会肝病学分会. 肝硬化诊治指南.实用肝脏病杂志,2019,22(6):770-792. [21] Driever EG, von Meijenfeldt FA, Adelmeijer J, et al. Nonmalignant portal vein thrombi in patients with cirrhosis consist of intimal fibrosis with or without a fibrin-rich thrombus. Hepatology. 2022,75(4):898-911. [22] Rodriguez-Castro K I , Vitale A , Fadin M,et al.A prediction model for successful lanticoagulation in cirrhotic portalvein thrombosis. Eur J Gastroenterol Hepatol,2019,31(1):34-42. |